Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.15%
0%
12.15%
6 Months
126.42%
0%
126.42%
1 Year
391.8%
0%
391.8%
2 Years
248.84%
0%
248.84%
3 Years
156.41%
0%
156.41%
4 Years
10.5%
0%
10.5%
5 Years
-53.85%
0%
-53.85%
ImmuPharma Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.65%
EBIT Growth (5y)
9.45%
EBIT to Interest (avg)
-3.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
0.03
Tax Ratio
28.68%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
64.96
EV to EBIT
-23.46
EV to EBITDA
-24.11
EV to Capital Employed
-64.57
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-353.04%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-2.90
-5.00
42.00%
Interest
0.00
0.10
-100.00%
Exceptional Items
0.00
-1.40
100.00%
Consolidate Net Profit
-3.80
-8.20
53.66%
Operating Profit Margin (Excl OI)
0.00%
-43,598.40%
4,359.84%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is -100.00% vs 0.00% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is 53.66% vs -18.84% in Dec 2021
About ImmuPharma Plc 
ImmuPharma Plc
Pharmaceuticals & Biotechnology
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
Company Coordinates 
Company Details
52 Grosvenor Gardens , LONDON None : SW1W 0AU
Registrar Details






